المؤلفون: Tacconelli, E, Carrara, E, Savoldi, A, Harbarth, S, Mendelson, M, Monnet, DL, Pulcini, C, Kahlmeter, G, Kluytmans, J, Carmeli, Y, Ouellette, M, Outterson, K, Patel, J, Cavaleri, M, Cox, EM, Houchens, CR, Grayson, ML, Hansen, P, Singh, N, Theuretzbacher, U, Magrini, N

المصدر: The Lancet. Infectious diseases. 18(3):318-327

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:137757042

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Hofmeyer KA; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC, USA., Ventura CL; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC, USA., Armstrong KL; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC, USA., Houchens CR; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC, USA., Patel S; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC, USA., Disbrow GL; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC, USA., Johnson RA; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC, USA.

مؤلفون مشاركون: Project NextGen Line of Effort Leads

المصدر: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Jul 19; Vol. 79 (1), pp. 115-121.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE

مواضيع طبية MeSH: COVID-19 Vaccines* , COVID-19*/prevention & control , COVID-19*/epidemiology , SARS-CoV-2*/immunology , Public-Private Sector Partnerships*, Humans ; United States ; Vaccine Development ; COVID-19 Drug Treatment ; Antiviral Agents/therapeutic use ; Drug Development/trends ; Pandemics/prevention & control

SCR Organism: SARS-CoV-2 variants

المؤلفون: Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA., Hejazi NS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Biostatistics, T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA., Blette B; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA., Carpp LN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Benkeser D; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA., Montefiori DC; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA., McDermott AB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Fong Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Janes HE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Deng W; Moderna, Inc., Cambridge, MA 02139, USA., Zhou H; Moderna, Inc., Cambridge, MA 02139, USA., Houchens CR; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA., Martins K; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA., Jayashankar L; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA., Flach B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Lin BC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., O'Connell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., McDanal C; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA., Eaton A; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA., Sarzotti-Kelsoe M; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA., Lu Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Kenny A; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA., Carone M; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA., Huynh C; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA., Miller J; Moderna, Inc., Cambridge, MA 02139, USA., El Sahly HM; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA., Baden LR; Brigham and Women's Hospital, Boston, MA 02115, USA., Jackson LA; Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA., Campbell TB; Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Clark J; Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA., Andrasik MP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA., Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Pajon R; Moderna, Inc., Cambridge, MA 02139, USA., Follmann D; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Donis RO; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA., Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA., On Behalf Of The Immune Assays, Moderna Inc, Coronavirus Vaccine Prevention Network CoVPN/Coronavirus Efficacy Cove, United States Government Usg/CoVPN Biostatistics Teams

المصدر: Viruses [Viruses] 2023 Sep 29; Vol. 15 (10). Date of Electronic Publication: 2023 Sep 29.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE

مواضيع طبية MeSH: 2019-nCoV Vaccine mRNA-1273* , COVID-19*/prevention & control, Humans ; Antibodies, Neutralizing ; Antibodies, Viral ; Immunoglobulin G ; Vaccine Efficacy

المؤلفون: Parish LA; CBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC 20201, USA., Stavale EJ; CBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC 20201, USA., Houchens CR; CBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC 20201, USA., Wolfe DN; CBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS), Washington, DC 20201, USA.

المصدر: Vaccines [Vaccines (Basel)] 2023 Jun 19; Vol. 11 (6). Date of Electronic Publication: 2023 Jun 19.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE

المؤلفون: Benkeser D; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA., Montefiori DC; Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA., McDermott AB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Fong Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Janes HE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Deng W; Moderna Inc., Cambridge, MA 02139, USA., Zhou H; Moderna Inc., Cambridge, MA 02139, USA., Houchens CR; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA., Martins K; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA., Jayashankar L; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA., Castellino F; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA., Flach B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Lin BC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., O'Connell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., McDanal C; Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA., Eaton A; Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA., Sarzotti-Kelsoe M; Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA., Lu Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Borate B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., van der Laan LWP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Hejazi NS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Biostatistics, T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA., Kenny A; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA., Carone M; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA., Williamson BD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA., Garver J; Battelle, West Jefferson, OH 43162, USA., Altonen E; Battelle, West Jefferson, OH 43162, USA., Rudge T; Battelle, West Jefferson, OH 43162, USA., Huynh C; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA., Miller J; Moderna Inc., Cambridge, MA 02139, USA., El Sahly HM; Baylor College of Medicine, Houston, TX 77030, USA., Baden LR; Brigham and Women's Hospital, Boston, MA 02115, USA., Frey S; Department of Internal Medicine, Saint Louis University, St. Louis, MO 63110, USA., Malkin E; Vaccine Research Unit, School of Medicine and Health Sciences, George Washington University, Washington, DC 20052, USA., Spector SA; Division of Pediatric Infectious Diseases, University of California, San Diego, La Jolla, CA 92093, USA.; Rady Children's Hospital, San Diego, CA 92123, USA., Andrasik MP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98115, USA., Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Carpp LN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Pajon R; Moderna Inc., Cambridge, MA 02139, USA., Follmann D; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Donis RO; Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA., Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA.

مؤلفون مشاركون: Immune Assays, Moderna Inc., Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE), United States Government (USG)/CoVPN Biostatistics Teams

المصدر: Science translational medicine [Sci Transl Med] 2023 Apr 19; Vol. 15 (692), pp. eade9078. Date of Electronic Publication: 2023 Apr 19.

نوع المنشور: Randomized Controlled Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE

مواضيع طبية MeSH: 2019-nCoV Vaccine mRNA-1273* , COVID-19*/prevention & control, Humans ; Vaccine Efficacy ; Antibodies, Neutralizing ; Immunoglobulin G ; Antibodies, Viral

المؤلفون: Fong Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Global Health, University of Washington, Seattle, WA, 98195, USA., Benkeser D; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA., Carpp LN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Áñez G; Novavax, Inc., Gaithersburg, MD, USA., Woo W; Novavax, Inc., Gaithersburg, MD, USA., McGarry A; Novavax, Inc., Gaithersburg, MD, USA., Dunkle LM; Novavax, Inc., Gaithersburg, MD, USA., Cho I; Novavax, Inc., Gaithersburg, MD, USA., Houchens CR; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Martins K; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Jayashankar L; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Castellino F; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Petropoulos CJ; LabCorp-Monogram Biosciences, South San Francisco, CA, USA., Leith A; Nexelis, Seattle, WA, USA., Haugaard D; Nexelis, Seattle, WA, USA., Webb B; Nexelis, Seattle, WA, USA., Lu Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Borate B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., van der Laan LWP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Statistics, University of Washington, Seattle, WA, USA., Hejazi NS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Biostatistics, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA., Randhawa AK; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Andrasik MP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Hutter J; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA., Keshtkar-Jahromi M; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA., Beresnev TH; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA., Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Follmann D; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Ake JA; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Gay CL; University of North Carolina School of Medicine, Chapel Hill, NC, USA., Kotloff KL; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Donis RO; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. pgilbert@fredhutch.org.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. pgilbert@fredhutch.org.; Department of Biostatistics, School of Public Health, University of Washington, Seattle, WA, USA. pgilbert@fredhutch.org.

مؤلفون مشاركون: Immune Assays Team, Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team, United States Government (USG)/CoVPN Biostatistics Team

المصدر: Nature communications [Nat Commun] 2023 Mar 22; Vol. 14 (1), pp. 1581. Date of Electronic Publication: 2023 Mar 22.

نوع المنشور: Published Erratum

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: PubMed not MEDLINE; MEDLINE

المؤلفون: Benkeser D; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA., Fong Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Janes HE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Kelly EJ; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Hirsch I; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Sproule S; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Stanley AM; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Maaske J; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Villafana T; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Houchens CR; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, Department of Health and Human Services, Washington, DC, USA., Martins K; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, Department of Health and Human Services, Washington, DC, USA., Jayashankar L; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, Department of Health and Human Services, Washington, DC, USA., Castellino F; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, Department of Health and Human Services, Washington, DC, USA., Ayala V; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, Department of Health and Human Services, Washington, DC, USA., Petropoulos CJ; LabCorp-Monogram Biosciences, South San Francisco, CA, USA., Leith A; Nexelis, Seattle, WA, USA., Haugaard D; Nexelis, Seattle, WA, USA., Webb B; Nexelis, Seattle, WA, USA., Lu Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Borate B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., van der Laan LWP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Statistics, University of Washington, Seattle, WA, USA., Hejazi NS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Biostatistics, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA., Carpp LN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Randhawa AK; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Andrasik MP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Isaacs MB; Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA., Makhene M; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Tong T; Vaccine Translational Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Robb ML; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Corey L; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA., Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Follmann D; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Hoffman C; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, Department of Health and Human Services, Washington, DC, USA., Falsey AR; Division of Infectious Diseases, Department of Medicine, University of Rochester, Rochester, NY, USA., Sobieszczyk M; Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, USA., Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Donis RO; Biomedical Advanced Research and Development Authority, Administration for Strategic Preparedness and Response, Department of Health and Human Services, Washington, DC, USA., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. pgilbert@fredhutch.org.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. pgilbert@fredhutch.org.; Department of Biostatistics, School of Public Health, University of Washington, Seattle, WA, USA. pgilbert@fredhutch.org.

مؤلفون مشاركون: AstraZeneca AZD1222 Clinical Study Group, Immune Assays Team, United States Government (USG)/CoVPN Biostatistics Team

المصدر: NPJ vaccines [NPJ Vaccines] 2023 Mar 11; Vol. 8 (1), pp. 36. Date of Electronic Publication: 2023 Mar 11.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Nature in partnership with the Sealy Center for Vaccine Development Country of Publication: England NLM ID: 101699863 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-0105 (Electronic) Linking ISSN: 20590105 NLM ISO Abbreviation: NPJ Vaccines Subsets: PubMed not MEDLINE

المؤلفون: Fong Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Global Health, University of Washington, Seattle, WA, 98195, USA., Benkeser D; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA., Carpp LN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Áñez G; Novavax, Inc., Gaithersburg, MD, USA., Woo W; Novavax, Inc., Gaithersburg, MD, USA., McGarry A; Novavax, Inc., Gaithersburg, MD, USA., Dunkle LM; Novavax, Inc., Gaithersburg, MD, USA., Cho I; Novavax, Inc., Gaithersburg, MD, USA., Houchens CR; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Martins K; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Jayashankar L; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Castellino F; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Petropoulos CJ; LabCorp-Monogram Biosciences, South San Francisco, CA, USA., Leith A; Nexelis, Seattle, WA, USA., Haugaard D; Nexelis, Seattle, WA, USA., Webb B; Nexelis, Seattle, WA, USA., Lu Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Borate B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., van der Laan LWP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Statistics, University of Washington, Seattle, WA, USA., Hejazi NS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Biostatistics, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA., Randhawa AK; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Andrasik MP; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Hutter J; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA., Keshtkar-Jahromi M; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA., Beresnev TH; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA., Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Follmann D; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Ake JA; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA., Gay CL; University of North Carolina School of Medicine, Chapel Hill, NC, USA., Kotloff KL; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA., Koup RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Donis RO; Biomedical Advanced Research and Development Authority, Washington, DC, USA., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. pgilbert@fredhutch.org.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. pgilbert@fredhutch.org.; Department of Biostatistics, School of Public Health, University of Washington, Seattle, WA, USA. pgilbert@fredhutch.org.

مؤلفون مشاركون: Immune Assays Team, Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team, United States Government (USG)/CoVPN Biostatistics Team

المصدر: Nature communications [Nat Commun] 2023 Jan 19; Vol. 14 (1), pp. 331. Date of Electronic Publication: 2023 Jan 19.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

مواضيع طبية MeSH: COVID-19*/prevention & control, Humans ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines ; Immunoglobulin G ; SARS-CoV-2 ; Vaccine Efficacy ; Clinical Trials, Phase III as Topic